儿科RISE:为儿童癌症开发针对贫困人口的现金支持干预措施
Colleen A Kelly1,2,3,4, Morgan A Paul5, Jennifer Kellett1
1Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Pediatric blood & cancer
|October 15, 2025
概括
儿科RISE,一个直接的现金支持计划,对于患有癌症的低收入儿童来说,证明是可以接受和有价值的,在不影响政府福利的情况下减少了困难. 目前正在进行改进,以增加支持的持续时间和金额.
科学领域:
- 儿科瘤学 儿科瘤学
- 健康 公平 卫生 公平
- 社会经济干预措施 社会经济干预
背景情况:
- 贫困与儿童癌症的更糟糕结果有关,但在儿科瘤学中没有财政支持干预措施.
- 直接现金支持计划显示出改善儿童健康结果的希望.
- 儿童资源干预以支持公平 (RISE) 是为了解决儿童癌症患者的经济困难而开发的.
研究的目的:
- 试点和完善儿科RISE干预,这是一项针对患有癌症的低收入儿童的新型直接现金支持计划.
- 评估儿童RISE计划的可接受性,满意度和使用障碍.
- 根据家长的反和结果,为儿童RISE干预的改进提供信息.
主要方法:
- 在接受癌症治疗的低收入儿童中进行了一项单臂试点研究.
- 参与者每月两次获得现金支付,并在三个月内接受可选福利咨询.
- 用家长调查和定性访谈来评估干预的可行性和影响.
主要成果:
- 家庭获得了所有预期的现金支付,利用资金满足基本需求,并报告减少了物质困难.
- 儿童RISE干预被认为是可以接受和有用的,没有报告政府福利的损失.
- 父母表示需要更大的现金支出和更长的干预时间来解决与治疗相关的收入损失.
结论:
- 儿科RISE干预对儿科癌症患者来说是可以接受和有价值的,有效地减轻了政府福利的风险.
- 父母反引导了改进,包括增加支付金额和延长期限.
- 一个精细的多站点随机试验目前正在评估增强的儿科RISE干预.
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
01:21Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
252
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
252